Dr. Timm Bredehorn-Mayr is an Eye Surgeon and the Chief of four ophthalmology practices in the Harz region, of Germany which lies between Brunswick, Magdeburg and Halle. With a limited number of ophthalmologists in the region, his workload is already a challenge, but the Covid-19 pandemic introduced new pressures. The Toul Meditech Operio® has provided solutions in this environment.
Adaptability and Flexibility in a Challenging Environment
Dr. Bredehorn-Mayr oversees ophthalmology practices in Aschersleben, Halberstadt, Staβfurt and Halle. With a lack of ophthalmologists in the region, he has a lot of patients and travels from clinic-to-clinic daily.
“We have small operating theaters In Aschersleben and Halberstadt, from which, we can carry out small procedures, such as intravitreal injections. And we have access to a very modern operating theatre in Magdeburg that we can hire, which we use for cataract surgery. However, for the operating theaters in Aschersleben and Halberstadt, it is not easy to create a complete very high quality operating theater environment, with clean room characteristics. This gave me the idea to look for a smaller tool that makes clean air,” he explained. “Before becoming familiar with Toul Meditech Operio®, I became aware of the SurgiCube®, while looking on the Internet. Before you build up something like this, you look for the opinions and feedback of people who have the same idea. And then I noticed that the SurgiCube® was associated with Dr. Gerrit Melles. I have known Mr. Melles since he was an assistant in Rotterdam, The Netherlands. I know he is a genius, so I was reassured that it must be a very good product.”
Following this, Dr. Bredehorn-Mayr contacted Ramon Hilberink of SurgiCube® and Toul Meditech in Vierpolders, The Netherlands, who visited Halberstadt to give a small demonstration of the product. Dr. Bredehorn-Mayr then had the opportunity to visit a private clinic in Delft, also in The Netherlands, to explore the product being used in clinical practice. Alongside use of the SurgiCube® for ophthalmic surgeries like cataract surgery, the Delft clinic also has a dedicated procedure room equipped with a Toul Meditech Operio®, which is used for intravitreal injection therapies.
“It was amazing,“ he said. “I decided that the Toul Meditech Operio® would be very good for the intravitreal injections that we need to do in my clinics in Germany. The other alternative was to build a very big conventional air conditioner in the operating rooms at a cost of something like €30,000 to €40,000. The Toul Meditech Operio® was much less expensive.”
A Small But Effective Solution
“The most important point is that you have a small machine that is making very clean air in the area that you are working in. It’s a small solution, but also the cost-benefit is significant, of course,” he remarked, “I have two operating theaters in Halberstadt and Aschersleben, and a Toul Meditech Operio® in both places. We have already completed more than 3,000 intravitreal injections since acquiring the Operio®.”
The two systems were first used in the operating theaters to provide really clean laminar flow directly during operations, but with the onset of the Covid-19 pandemic, they proved their added-value.
“Having sterile air on the field of operations is amazing, because you can be sure that no particle is coming from elsewhere, and the sterility is so directed to your focus in the operations. That gives me a very good feeling,” said Dr. Bredehorn-Mayr.
“Additionally, now, after operating has finished, we place the machines in diagnostic and patient-related areas in our clinic, because they remove particles that may carry bacteria and Covid-19 viruses,” he added. “Therefore, I have very clean air in my practice. The pandemic has had a big impact: we have less patients, we need more space to guarantee the social distancing, we have a lot of measures to implement to protect against Covid-19, and there is an anxiety within my team and my patients. It’s a very big stress. Therefore, with the Operio® on the floor, you have a better feeling about it all.”
Biography: Dr. Timm Bredehorn-Mayr
Dr. Timm Bredehorn-Mayr is a leading Ophthalmologist in Germany. He is Chief of four ophthalmology practices in Aschersleben, Halberstadt, Staßfurt and Halle in Germany. After graduating in Medicine (Magna cum laude) from CAU Kiel and at the Georg-August-University in Göttingen, Germany, he specialized in ophthalmology in prestigious clinics in Leiden, the Netherlands and Halle-Wittenberg in Germany. During this time, he developed his expertise in corneal transplantation and other cutting-edge ophthalmology techniques.
For six years, Dr. Bredehorn-Mayr was Medical Director for the DSO-G (Non-Profit Society for Tissue Transplantation). He was also Deputy Head of the Halle Eye Bank. Following this, he was appointed Consultant of Strabology, Children and Neuro-ophthalmology at the University of Ophthalmology MLU in Halle-Wittenberg, Germany, and became Director of the Halle (Saale) Eye Bank.
Since 2014, Dr. Bredehorn-Mayr has been an ophthalmologist in free practice working in Aschersleben, Halberstadt, Staßfurt and Halle, in Germany.
Dr. Bredehorn-Mayr has authored or co-authored over 30 scientific publications in ophthalmology. He has also co-authored two books on eye banking – one in German and one in English: “Augenbanken”: Hsg. von Wilhelm F. W., Duncker G. I: W., Bredehorn T., de Gruyter Walter Berlin 2002; and “Eye banking“: Hsg. von Bredehorn-Mayr T., Duncker G. I. W., Armitage W. J. Karger Basel, 2009.
Dr. Timm Bredehorn-Mayr, 2021-06-01
Providing a Safe Environment for Intraocular Injections
Mr. Shahram Kashani is Consultant Ophthalmic Surgeon and the Medical Retinal Lead for the East Sussex National Health Service (NHS) Trust, which runs Conquest Hospital, Eastbourne District General Hospital and Bexhill Hospital, all in East Sussex, UK. The Trust originally purchased a Toul Meditech Operio® to expand capacity for intravitreal injections, such as anti-VEGF therapy, streamline its ophthalmology services and reduce pressure on other facilities, such as its main operating theaters. However, since the subsequent start of the Covid-19 pandemic, it has proved invaluable in enabling sight-saving intravitreal injections to continue, at a time when it was not possible to access parts of the Trust’s healthcare facilities.
Before the Trust purchased the Toul Meditech Operio®, its ophthalmology team utilized one clean room for carrying out intravitreal injections, but with significant rising demand for the injections for a variety of retinal disorders, this set up became insufficient.
“The number of patients requiring intravitreal injections was increasing at a significant pace. We often worked weekends and evenings to catch up with the workload, and that proved very tiring,” explained Mr. Kashani. “To cope with demand, we were going to have a second clean room, but the cost of installing ventilation would have been huge, and it would have taken a long time to get this approved through the numerous panels and committees involved. Then, somebody mentioned that a device existed, which could help change a room into an environment suitable for injections, as long as certain criteria were met: The Toul Meditech Operio®. We traveled up to Aintree Hospital, in Merseyside, UK, to see the machine there in action. It was great. So, we purchased one, and have actually recently acquired our second one.”
“The Toul Meditech Operio® has made life a lot easier, because we are able to convert almost any room that meets the specifications, into an injection room, and deliver those much needed injections safely,” he continued. “As it turned out, after we bought the system, the ventilation completely stopped working in our first injection room, so we weren’t able to use it anymore. Without the Operio®, we would have had to use an operating theater, which is obviously not a very good setting for delivering high volume intravitreal injection therapy.”
Growth in demand for intraocular injections
The demand for intravitreal injections has changed drastically in the last decade as treatments for macular degeneration and other retinal disorders have been approved and included in healthcare guidelines.
“Patients with retinal disorders, which account for most cases of blindness in the UK, had sudden access to sight-saving injections. At present we carry out around 7,000 to 8,000 episodes of injections per year. That’s a huge workload to get through! In every session, you can complete between 12 to 20 injections,” remarked Mr. Kashani. “Quite often, clinic rooms are occupied for other procedures. So, the nice thing about Toul Meditech Operio® is that you can also move it around, if you want to, as long as the other criteria within the room match the conditions specified by the Royal College of Ophthalmologists. That gave us flexibility and accessibility. We were able to essentially manage the intravitreal injection service without having to necessarily work at weekends or evenings, and it allowed us to maximize our capacity during the week.”
“The Toul Meditech Operio® brought us additional capacity quickly and cost-effectively. Swift solutions are essential for patients that are time critical. They're very important. You can't even wait a week with some of these patients. You have to have a solution right at
hand,” he added. “You don't need that much space to do Anti-VEGF injections, but at the same time, one in 1,000 can lose their sight and go blind from them, so patient safety is very important to us. We want to be able to deliver care in a safe setting.”
As retinal injections are so time-critical and because there are so many patients who need treatment, the burden of disease on patients and clinicians, and commissioners in the East Sussex region is significant.
“It is also very important to modernize the intravitreal injection service as the patient numbers will increase year on year across the service with most patients requiring monitoring or treatment for the next 2-3 years,” said Mr. Kashani. “By modernizing, I mean designing up to date treatment protocols, training non-medical injectors and employing something like the Toul Meditech Operio® to enable you to use clinical rooms or areas that you wouldn't normally for delivering treatment and injections’’
“And managing cost is also extremely important,” he said. “Operating theaters are expensive to set-up and run and for retinal injections, you don’t really need that much space. The Operio® enable us to free-up the theater for other things.”
Navigating the Pressures of the Pandemic
When the Covid-19 pandemic took a hold, Mr. Kashani’s team had to move out of the East Sussex NHS Trust’s acute sites, but with the Toul Meditech Operio® and access to a Community Hospital, they could continue their work.
“Pre-Covid-19, it would be unthinkable to delay injections for a time-critical condition, but when the pandemic hit us, there were new considerations about who we should treat and who we should delay treatment. These were unthinkable times. We had to adapt very quickly in order to manage that risk, but because we were able to use the Community Hospital, and we had the Toul Meditech Operio®, we had extra capacity,” said Mr. Kashani. “The retinal injection service was one of the only services that was running fully alongside the emergency service. Everything else came to a halt for a good few months, but we were lucky enough to be able to deliver our treatment for time-critical conditions in a timely manner for those patients who wanted to attend clinics. However, there is still a backlog, which will continue post-Covid. If retinal injections were to take up operating theatre space, the ophthalmology service would never recover, but with the right set up and equipment like the Operio®, some of the diagnostics and even treatment delivery could be done in the community.”
Keeping Up the Pace
The Toul Meditech Operio® has undoubtedly made a significant difference to the work of Mr. Kashani and his team.
“The Toul Meditech Operio® is one of the best things that we have purchased,” he said. “With the Operio®, we can by-pass so many things that might slow us down. The device is very user-friendly for surgeon and patient. It has proven data of minimizing infection and enables us to work with tight budgets. We can use different areas of the clinic, which has been transformative in the Covid-19 pandemic. It has really helped us.”
Mr. Shahram Kashani
Mr. Shahram Kashani is a Consultant Ophthalmic Surgeon at the East Sussex NHS Trust in the UK. He is a general ophthalmologist with a specialist interest in complex cataract surgery with premium lens implant and management of challenging retinal disorders. He also consults privately at the Eastbourne Eye Clinic in Eastbourne, UK.
Mr. Kashani is a UK-trained ophthalmologist, who graduated from St George’s Hospital Medical School in London in 1998. He has extensive experience in managing general ophthalmic pathology, having trained at various other prestigious ophthalmic units in London including Kings College Hospital, Charing Cross and Western Eye Hospital, Chelsea and Westminster Hospital as well as three years at the world renowned Moorfields Eye Hospital, where he was also selected and completed advanced subspecialty fellowship training in management of eye conditions including macular degeneration, diabetic eye disease, retinal vein occlusions, inflammatory eye disease and complex cataract surgery.
Mr. Kashani has an active interest in research and has produced over 40 peer reviewed publications and over 25 national and international presentations. He is a Member of the European Society of Retinal Specialists (EURETINA) and European Society of Cataract and Refractive Surgeons (ESCRS) and attends national and international meetings regularly to keep his professional development with the latest technology in his field. He is one of only a handful of surgeons who has achieved the prestigious membership status of the Royal College of Physicians, as well as obtaining the fellowship status from the Royal College of Ophthalmologists.
Mr. Kashani has won several awards for his teaching skills and has particular interest in developing the role of optometrists and nurse specialists in delivering modern ophthalmic care.
Mr. Shahram Kashani, 2021-06-01
Preventing Complications in Orthopedic Surgery
Some years ago, the Vestre Viken Hospital, in Drammen, Norway, recognized the benefits of the Toul Meditech Operio® for orthopedic surgery. Dr. Lukas Månsson, Chief of Services for the Department of Orthopedic Surgery and Emergency Medicine and Orthopedic Surgeon at the Hospital, has used the system since it was installed in 2015, and values the contribution that it has made to infection control, as well as cost savings.
A Better Option for Clean Air
Orthopedic surgery is carried out in two different hospitals within the Vestre Viken Hospital Trust. As part of the planning of a major renovation of existing operation theaters in 2014, the orthopedic team investigated new clean air systems.
“With inconsistent data regarding the performance of LAF (Laminar Air Flow) ceilings, we looked for alternatives in the market and found out about Toul Meditech Operio®,” said Dr. Månsson. “It became a choice between a LAF ceiling and the Toul Meditech Operio® . Toul Meditech Operio® stood out for three main reasons. Firstly, there was good and consistent data published on its performance. Both preclinical and subclinical papers. Secondly, it appealed because it gives us better control of the clean air in the operation, that can be focused on the surgery site and on the instrument table. And the last point that was relevant was cost. On life-cycle cost, the Operio® offers savings.”
Infection Control System
The Toul Meditech Operio® has become a part of the Hospital’s infection control system.
“We have a very efficient or effective infection control program and have reduced the risk of many infections through this,” remarked Dr. Månsson. “It's hard to say which part has contributed to what in a complex system, but we have been able to achieve a relatively low incidence of circo synovial infection in the context of joint replacement that is class leading on a global scale. That, of course, is the main benefit of the Toul Meditech Operio®. It is part of a very good system.”
Since 2015, the Vestre Viken Hospital has used the Toul Meditech for more than 5,000 joint replacements and over 3,000 spinal surgeries, as well as other surgeries. It is now used for all joint replacements and spinal surgeries.
Firstly, the system was used it in the Vestre Viken’s minor hospital. While the main operation suite in this hospital was renovated in December 2019, the Toul Meditech Operio® enabled joint replacement surgery to be continued in the day surgery unit.
“Without the Toul Meditech Operio® , that would not have been possible, because that was an old (20 years old) day surgery unit, which was originally designed for non-ultraclean surgery” said Dr. Månsson. “With the Toul system, we were confident that we had a clean air system that we could employ to utilize all the space that we had.”
Adopting New Technology
Within a short space of time, the Toul Meditech® was easily integrated into the surgical processes of the orthopedic department.
“With Toul Meditech Operio®, you do have to look through your processes. You have to ensure that the nurses and surgeons that use the system really know and understand it,” emphasized Dr. Månsson. “However, if you accept it and learn how to use it, you can
maintain good efficiency, but you need to adapt it to your work level, or adapt your work-level to that kind of equipment.”
The COVID-19 pandemic has had an impact Norway, although so far not as severely as some other countries.
“Considering the effects of the pandemic on the world in general, we have a huge backlog on elective surgeries on a global scale And of course, every technology that can reduce the risk of major surgery complications helps capacity in this context,” said Dr. Månsson. “Some orthopedic conditions already require enormous amounts of resources to treat, with long surgeries, and long stays at the hospital, but one of the biggest cause of waste in the healthcare environment is major complications, as well as over overtreatment, So everything we can do to reduce complications will free up capacity to address that backlog. I think it's extremely important that during the post-pandemic period we consider that we look at infection control and learn as much as possible from the pandemic experience. Infection control must be regarded as an essential system. And in infection control with regards to surgery, I would predict surgery with the Toul Meditech Operio®, can be a cost-efficient part of that.”
Dr. Lukas Månsson
Dr. Lukas Månsson is the Chief of Services for the Department of Orthopedic Surgery and Emergency Medicine at the Vestre Viken Hospital, Drammen, Norway. He is also an orthopedic surgeon, mainly in hip, shoulder and trauma surgery.
Dr. Månsson has worked at the Hospital for 16 years. He has worked as an orthopedic surgeon at several different hospitals before that, in both Norway and Sweden.
Dr. Lukas Månsson, 2021-06-01
Improving cataract surgery workflow
Laminar air device ensures safe patiens flow during COVID pandemic.
Dermot McGrath reports
Tomas Hansson, CEO, 2021-05-27
ISO Class 5 results from Italy
In December 2019, environmental monitoring of Operio took place in the Hospital of Bolzano in Italy that demonstrated the effective area with the device on is ISO Class 5 compliant.
A particle counter was used for measuring the particulate count when Operio was turned off compared to turned on. The test demonstrated that both 0.3 and 0.5 μm particles fulfils ISO Class 5 with concentrations of 0 particles/m3 within two minutes after switching on the device.
Tomas Hansson, CEO, Toul Meditech AB, 2020-06-08